QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:OGI

OrganiGram Competitors

$2.82
-0.24 (-7.84 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.62
Now: $2.82
$3.07
50-Day Range
$1.63
MA: $2.70
$6.00
52-Week Range
$1.01
Now: $2.82
$6.45
Volume15.05 million shs
Average Volume28.72 million shs
Market Capitalization$655.00 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3

Competitors

OrganiGram (NASDAQ:OGI) Vs. XNCR, GBT, DCPH, AXSM, PRLD, and RCUS

Should you be buying OGI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to OrganiGram, including Xencor (XNCR), Global Blood Therapeutics (GBT), Deciphera Pharmaceuticals (DCPH), Axsome Therapeutics (AXSM), Prelude Therapeutics (PRLD), and Arcus Biosciences (RCUS).

OrganiGram (NASDAQ:OGI) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. 3.7% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Xencor-113.40%-13.56%-12.03%

Earnings and Valuation

This table compares OrganiGram and Xencor's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million10.14$-101,290,000.00($0.08)-35.25
Xencor$156.70 million16.34$26.88 million$0.4696.07

Xencor has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Xencor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram08402.33
Xencor20702.56

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Xencor has a consensus target price of $47.1111, indicating a potential upside of 6.61%. Given Xencor's stronger consensus rating and higher probable upside, analysts clearly believe Xencor is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Summary

Xencor beats OrganiGram on 10 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Global Blood Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Global Blood Therapeutics-332.94%-56.43%-39.32%

Earnings and Valuation

This table compares OrganiGram and Global Blood Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million10.14$-101,290,000.00($0.08)-35.25
Global Blood Therapeutics$2.11 million1,188.35$-266,770,000.00($4.71)-8.56

OrganiGram has higher revenue and earnings than Global Blood Therapeutics. OrganiGram is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Global Blood Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram08402.33
Global Blood Therapeutics051202.71

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Global Blood Therapeutics has a consensus target price of $93.8235, indicating a potential upside of 132.58%. Given Global Blood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Global Blood Therapeutics is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Summary

OrganiGram beats Global Blood Therapeutics on 8 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Earnings and Valuation

This table compares OrganiGram and Deciphera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million10.14$-101,290,000.00($0.08)-35.25
Deciphera Pharmaceuticals$25 million99.02$-192,260,000.00($4.48)-9.59

OrganiGram has higher revenue and earnings than Deciphera Pharmaceuticals. OrganiGram is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram08402.33
Deciphera Pharmaceuticals03602.67

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Deciphera Pharmaceuticals has a consensus target price of $69.4444, indicating a potential upside of 61.65%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Summary

Deciphera Pharmaceuticals beats OrganiGram on 8 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Axsome TherapeuticsN/A-62.33%-47.87%

Earnings and Valuation

This table compares OrganiGram and Axsome Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million10.14$-101,290,000.00($0.08)-35.25
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-32.94

Axsome Therapeutics has lower revenue, but higher earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Axsome Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram08402.33
Axsome Therapeutics101102.83

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Axsome Therapeutics has a consensus target price of $146.90, indicating a potential upside of 121.87%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.

Summary

Axsome Therapeutics beats OrganiGram on 8 of the 13 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Prelude Therapeutics (NASDAQ:PRLD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Prelude TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares OrganiGram and Prelude Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million10.14$-101,290,000.00($0.08)-35.25
Prelude TherapeuticsN/AN/AN/AN/AN/A

Prelude Therapeutics has lower revenue, but higher earnings than OrganiGram.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Prelude Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram08402.33
Prelude Therapeutics03002.00

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Prelude Therapeutics has a consensus target price of $41.3333, indicating a potential downside of 25.93%. Given OrganiGram's stronger consensus rating and higher probable upside, analysts clearly believe OrganiGram is more favorable than Prelude Therapeutics.

OrganiGram (NASDAQ:OGI) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are owned by institutional investors. 19.7% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Arcus Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Arcus Biosciences-112.63%-27.43%-20.96%

Earnings and Valuation

This table compares OrganiGram and Arcus Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million10.14$-101,290,000.00($0.08)-35.25
Arcus Biosciences$15 million157.77$-84,710,000.00($1.93)-17.30

Arcus Biosciences has lower revenue, but higher earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Arcus Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram08402.33
Arcus Biosciences00903.00

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Arcus Biosciences has a consensus target price of $49.9091, indicating a potential upside of 49.47%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Summary

Arcus Biosciences beats OrganiGram on 9 of the 14 factors compared between the two stocks.


OrganiGram Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xencor logo
XNCR
Xencor
1.0$44.19-1.3%$2.56 billion$156.70 million-31.56Analyst Upgrade
Insider Selling
Analyst Revision
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.34-4.9%$2.51 billion$2.11 million-8.73Analyst Revision
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$42.96-3.1%$2.48 billion$25 million-8.59
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$66.21-6.0%$2.47 billionN/A-24.61Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
PRLD
Prelude Therapeutics
1.0$55.80-6.7%$2.44 billionN/A0.00Upcoming Earnings
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.39-3.5%$2.37 billion$15 million-17.48Analyst Report
Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$141.71-4.3%$2.35 billion$120.28 million-143.14Decrease in Short Interest
IGMS
IGM Biosciences
2.0$74.77-8.7%$2.30 billionN/A-31.82Insider Selling
News Coverage
MORF
Morphic
1.1$69.09-3.5%$2.24 billion$16.98 million-44.29Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Gap Up
Amarin logo
AMRN
Amarin
1.6$5.72-1.9%$2.22 billion$429.76 million-114.38
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.45-0.3%$2.12 billion$963.01 million13.18
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$59.64-1.7%$2.08 billionN/A0.00Gap Up
Cryoport logo
CYRX
Cryoport
1.7$52.09-5.6%$2.07 billion$33.94 million-89.81Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.06-7.2%$2.07 billion$23.90 million-16.81Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Kura Oncology logo
KURA
Kura Oncology
1.6$31.02-3.7%$2.05 billionN/A-19.03Analyst Report
High Trading Volume
Analyst Revision
Generation Bio logo
GBIO
Generation Bio
1.6$34.63-15.3%$1.93 billionN/A0.00Upcoming Earnings
Analyst Report
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$21.00-8.7%$1.91 billionN/A-7.47
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$56.89-4.2%$1.90 billionN/A-31.61High Trading Volume
HRMY
Harmony Biosciences
1.4$33.02-5.0%$1.88 billionN/A0.00Analyst Downgrade
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$27.00-5.0%$1.86 billion$103.54 million-20.30Insider Selling
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$25.71-0.4%$1.84 billion$410,000.00-5.59Analyst Report
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$61.49-0.2%$1.82 billion$970,000.000.00Upcoming Earnings
Analyst Report
Increase in Short Interest
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.08-0.0%$1.80 billionN/A-10.12Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$43.55-0.2%$1.77 billionN/A0.00Upcoming Earnings
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$13.41-7.2%$1.71 billion$320,000.00-9.12Analyst Revision
Shattuck Labs logo
STTK
Shattuck Labs
1.3$40.50-1.9%$1.69 billionN/A0.00Upcoming Earnings
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.36-3.9%$1.67 billion$82.27 million-20.39
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$18.11-2.5%$1.65 billion$34.51 million-15.48Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.8$29.32-2.9%$1.64 billionN/A0.00Upcoming Earnings
News Coverage
ADCT
ADC Therapeutics
1.6$23.76-7.0%$1.64 billion$2.34 million-10.07News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$9.99-0.2%$1.61 billion$428.41 million14.48Insider Buying
Endo International logo
ENDP
Endo International
1.3$6.89-0.6%$1.59 billion$2.91 billion-10.13Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$35.24-0.2%$1.58 billionN/A0.00News Coverage
ORGO
Organogenesis
1.0$14.59-5.7%$1.57 billion$260.98 million-243.17
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.95-1.9%$1.55 billion$145.97 million-6.86Analyst Upgrade
Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$30.69-5.7%$1.54 billionN/A-3.33
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$21.90-0.7%$1.49 billionN/A-9.24Gap Down
Zymeworks logo
ZYME
Zymeworks
1.8$31.94-7.0%$1.47 billion$29.54 million-8.47Analyst Report
High Trading Volume
Increase in Short Interest
Analyst Revision
News Coverage
uniQure logo
QURE
uniQure
1.9$32.95-5.5%$1.47 billion$7.28 million-8.74Earnings Announcement
Analyst Report
Analyst Revision
NKTX
Nkarta
1.8$44.45-5.6%$1.45 billionN/A0.00
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$4.83-1.2%$1.45 billion$1.63 billion11.78Earnings Announcement
Analyst Report
Analyst Revision
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.3$38.00-44.1%$1.45 billion$14.87 million-14.18Upcoming Earnings
Analyst Downgrade
High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Trading Halted
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$39.61-15.1%$1.42 billionN/A0.00Upcoming Earnings
News Coverage
ATBPD
Antibe Therapeutics
0.1$3.64-8.0%$1.41 billion$7.51 million-6.07Gap Down
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$41.69-8.5%$1.41 billion$28.95 million-59.56Analyst Downgrade
Insider Selling
OLMA
Olema Pharmaceuticals
1.7$36.41-3.7%$1.40 billionN/A0.00
MacroGenics logo
MGNX
MacroGenics
1.6$24.08-2.5%$1.35 billion$64.19 million-7.69Analyst Report
Gap Up
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$33.23-1.4%$1.35 billionN/A-11.19Earnings Announcement
Analyst Report
Decrease in Short Interest
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.01-3.4%$1.35 billion$6.20 million-13.60Upcoming Earnings
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$26.34-4.0%$1.34 billion$175.34 million-15.49Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.